Physician profile
Dudley E Freeman
NPI 1821005372
$3,370.31
in general payments reported to CMS, 2019-2025
31 companies · $439 in 2025
The $439 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $358 · 2021: $541 · 2022: $658 · 2023: $696 · 2024: $285 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.79 |
| Education | $158.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $712.90 | 2019-2025 | Veozah |
| Abbvie INC. | $421.66 | 2019-2023 | |
| Daiichi Sankyo INC. | $360.32 | 2020-2025 | Injectafer, Enhertu |
| Exeltis, USA INC. | $321.89 | 2019-2023 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $315.76 | 2019-2023 | |
| Organon LLC | $162.00 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $148.34 | 2023-2025 | Gemtesa, Myfembree |
| Coopersurgical, INC. | $108.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $97.25 | 2019-2025 | Gardasil 9, M-M-R II |
| Acessa Health INC. | $80.83 | 2021 | |
| Lilly USA, LLC | $72.84 | 2021-2025 | Zepbound |
| Pfizer INC. | $65.05 | 2021-2024 | |
| Novo Nordisk INC | $57.90 | 2020-2022 | |
| Minerva Surgical, INC | $54.05 | 2022 | |
| Therapeuticsmd, INC. | $49.70 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baudax Bio INC. | $46.89 | 2021-2022 | |
| Innovation Technologies INC | $34.87 | 2023 | Irrisept |
| Sage Therapeutics, LLC | $33.65 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $28.41 | 2025 | |
| Boston Scientific Corporation | $25.28 | 2025 | Bulkamid |
| Pacira Pharmaceuticals Incorporated | $22.62 | 2025 | Exparel |
| Acella Pharmaceuticals, LLC | $18.51 | 2025 | NP Thyroid 60 |
| Urovant Sciences INC | $17.38 | 2022 | |
| Myovant Sciences INC. | $17.24 | 2021 | |
| Coloplast Corp | $16.60 | 2024 | |
| Medtronic, INC. | $14.74 | 2025 | Ligasure |
| Smith+Nephew, INC. | $14.55 | 2019 | |
| Lupin INC. | $12.89 | 2019 | |
| Allergan, INC. | $12.87 | 2020 | |
| Baxter Healthcare | $12.73 | 2023 | Perclot |
| Mayne Pharma Commercial LLC | $12.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dudley Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.